In this paper, we will provide an updated review of clinical, prognostic and therapeutic implications of BRAF mutations in NSCLC patients, citing the more recent literature; this topic is particularly relevant in consideration of the rapid evolution of the knowledge in this field in the last few years. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.